Professional Documents
Culture Documents
Abbas 2016
Abbas 2016
Abbas 2016
Effect of cervical Lidocaine-Prilocaine cream on pain perception during cop-
per T380A intrauterine device insertion among parous women: a randomized
double-blind controlled trial
PII: S0010-7824(16)30478-4
DOI: doi: 10.1016/j.contraception.2016.10.011
Reference: CON 8842
Please cite this article as: Abbas Ahmed M., Abdellah Mohamed S., Khalaf Mohamed,
Bahloul Mustafa, Abdellah Noura H., Ali Mohamed K., Abdelmagied Ahmed M., Effect
of cervical Lidocaine-Prilocaine cream on pain perception during copper T380A intrauter-
ine device insertion among parous women: a randomized double-blind controlled trial,
Contraception (2016), doi: 10.1016/j.contraception.2016.10.011
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
ACCEPTED MANUSCRIPT
T
Noura H. Abdellah b, Mohamed K. Ali a, Ahmed M. Abdelmagied a
P
RI
(a) MD., Department of Obstetrics & Gynecology, Faculty of Medicine. Assiut University, Assiut, Egypt.
SC
(b) MD., Department of Pharmaceuticals, Faculty of Pharmacy. Assiut University, Assiut, Egypt.
NU
* Corresponding author MA
Dr. Ahmed M. Abbas, MD
Department of Obstetrics and Gynecology,
Assiut University, Egypt
Women Health Hospital,
71511, Assiut Egypt
ED
1
ACCEPTED MANUSCRIPT
Abstract
Objective:
T
alleviating pain during copper T380A intrauterine device (IUD) insertion among parous
P
RI
women.
SC
Study design:
NU
Health Hospital, Egypt from October 2015 to April 2016 of parous women desiring
MA
copper IUD insertion. We randomized the subjects in a 1:1 ratio to LP cream or Placebo.
the anterior cervical lip, followed by 2 mL placed in the cervical canal using a Q-tip
applicator. The study endpoint was the subjects’ self-reported pain using a 10-cm Visual
PT
Analogue Scale (VAS) during cervical tenaculum placement, sound insertion, IUD
CE
between study groups as clinically significant. Also, the difference in the ease of
AC
insertion score using a 10-cm VAS with 0= very easy insertion, and 10= terribly difficult
Results:
The study included 120 women (n=60 in each group). LP cream reduces the median VAS
pain scores during tenaculum placement (2 vs. 4), sound insertion (3 vs. 6), and IUD
insertion (3 vs. 6.5) with p=0.0001 at all steps. A lower ease of insertion score was also
2
ACCEPTED MANUSCRIPT
side effects.
Conclusions:
P T
Use of cervical LP cream prior to copper T380A IUD insertion may alleviate the IUD
RI
insertion pain among parous women.
SC
Implications:
NU
T380A IUD insertion with no side effects. Further studies are needed to assess the
MA
women’s’ satisfaction from lying with a speculum in place for 7 minutes while waiting
Key words:
3
ACCEPTED MANUSCRIPT
1. Introduction:
for reduction of the unplanned pregnancy rate worldwide [1]. The intrauterine device
P T
(IUD) is a single procedure that provides reliable, effective and long term contraception
RI
for many women [2]. However, the insertion procedure can be associated with a
SC
troublesome degree of pain that prevent some women from choosing its use [3].
IUD insertion steps that can induce pain include application of the tenaculum to
NU
grasp the cervix; passing the sound for measuring the uterine length, introducing the
MA
IUD inserter tube; and release of the IUD inside the uterus [4]. Different interventions
have been described to decrease pain perception during IUD insertion with no
ED
eutectic mixture of two anesthetics; lidocaine 2.5% and prilocaine 2.5% in a ratio of 1:1
cream on the cervix prior to office hysteroscopy [12], and hysterosalpingography (HSG)
4
ACCEPTED MANUSCRIPT
[13] studied before and was an effective local anesthetic before minor gynecological
procedures.
A recent Cochrane review (2015), entailed different interventions for pain relief
P T
with IUD insertion, included a single randomized controlled trial of 92 women found LP
RI
cream was superior to placebo [14]. They expressed the need for more trials to prove
SC
the efficacy of its use [5].
NU
cream in alleviating pain during copper T380A IUD insertion among parous women.
MA
2. Materials and Methods:
Hospital, Egypt between the 1st of January 2016 and the 31st of May 2016. The Assiut
PT
We clinically evaluated all women attended the Family Planning Clinic during the
AC
study period requesting an IUD insertion and invited them to participate in the study if
they had no contraindications for insertion in accordance with WHO eligibility criteria
[16]. We recruited parous women as IUD is not requested by nulliparas or outside the
18-49 years old who did not receive any analgesics or misoprostol in the 24 hours prior
5
ACCEPTED MANUSCRIPT
All eligible participants included in the study signed a written informed consent
before participation. One of the study researchers approached all included women and
collected the baseline data. Then, he explained the standard 10-cm visual analog scale
P T
(VAS) to the participants for pain scoring [15]. The severity of pain was assessed with
RI
VAS (with 0= no pain and 10= worst imaginable pain). Each woman received a copper
SC
T380A IUD (ParaGard®T380A; Teva Pharmaceuticals USA, Inc. North Wales) for
insertion.
NU
We randomly assigned all participants in a 1:1 ratio into one of two groups:
MA
Lidocaine-prilocaine (LP group): women had LP anesthetic cream (Pridocaine®;
GLOBAL NAPI PHARMACEUTICALS (GNP), Egypt) placed into their cervix prior to
ED
insertion and Placebo group: women had an inert placebo cream created to be
random table and placed the allocation data in serially numbered sealed envelopes.
AC
Each envelope had a card noting the group identifier inside. A single pharmacist was
responsible for the manufacturing of the placebo cream and packaging of both
preparations into sterile tubes with labeling them as A and B. Only the Pharmacist
knew what was the medication in tube A and B, so neither the clinician nor the women
knew the type of the preparation. The clinician opened the envelopes according to the
order of attendance of women and used the tube A or B according to the card.
Four experienced gynecologists inserted the IUDs using the standard technique of
6
ACCEPTED MANUSCRIPT
speculum into the vagina and cleansed the cervix with povidone iodine. Seven minutes
prior to IUD insertion, 2 mL of the study cream was placed on the anterior lip of the
P T
level of internal os. The woman stayed lying in bed with the speculum in place till
RI
completing the insertion procedure. After 7 minutes exposure to the cream, the
SC
clinician grasped the cervix with a tenaculum, and inserted the uterine sound for
NU
complications such as uterine perforation, failure of insertion, and vasovagal reaction
MA
were recorded.
A research assistant standing beside the woman asked her to rate the intensity of
ED
pain at four different points; during tenaculum placement, during sound insertion, at
time of IUD insertion and 5 minutes after the end of insertion using the same 10-point
PT
VAS with a different sheet of paper at every point. After the end of procedure, the
CE
clinician assessed the ease of IUD insertion using the ease of insertion score (ES). The
AC
ES is a graduated VAS-like scale from zero to 10; in which 10 means terribly difficult
insertion and zero means very easy insertion. Finally, the clinician asked all women
about the need for any additional analgesics at 15 minutes after completing the
contacted the participants by telephone 24 hours later to report any side effects of the
The primary outcome was the difference in pain VAS scores during IUD insertion.
The secondary outcomes included the difference in pain scores during tenaculum
7
ACCEPTED MANUSCRIPT
application, insertion of sound and five minutes after insertion, the ease of IUD
insertion, the number of women who need analgesics after insertion, and the side
P T
Sample size was calculated using the Open Epi software program, version 2.3.1.
RI
Most of previous studies consider a median VAS pain score with IUD insertion 5 cm in
SC
the placebo group [5]. We estimated that a 2 cm difference in the VAS pain score to be
clinically significant. Using two sided chi-square (χ2) test with α of 0.05, a total sample
NU
size of at least 110 women in both groups (55 in each group) using 80% power would
MA
be necessary to detect 2 cm difference in the VAS pain score with the use of LP cream
[Odds Ratio=0.6]. We expected a 10% dropout rate; and therefore recruited 120
ED
All data were analyzed using SPSS software Chicago, IL, USA, version 21.
PT
Comparison between categorical variables in both groups was done by Chi-square test
CE
or Fisher’s exact test if appropriate and continuous variables were compared using
AC
Student T-test. For statistical analysis, we tested the different pain scores for normality
by Shapiro-Wilkes test and they were not normally distributed, so they are presented
as median scores and compared using the Mann-Whitney test. The ease of insertion
scores were normally distributed, so they are presented as mean ± SD and compared
with the Student T-test. A multivariate stepwise linear regression model was
conducted, after controlling for the interventional arm, to assess to assess if any
baseline characteristics were associated with increased pain. We considered P value <
8
ACCEPTED MANUSCRIPT
3- Results:
We recruited 131 women to participate in the study. Eight women have been
excluded: five women had uterine abnormalities and three women had received
P T
analgesics prior to insertion. Moreover, three women declined participation in the
RI
study after signing the approval consent form. We randomly assigned the remaining
SC
120 women into both groups (Figure 1, the study flowchart). The day of the menstrual
NU
Table 1 show that both groups were comparable in the baseline characteristics.
MA
Table 2 shows the median pain scores for both groups. Women in the LP group were
more likely to report clinically significant lower pain scores during IUD insertion, during
ED
tenaculum placement and uterine sound insertion (p=0.0001). The difference in pain
scores at 5 min after IUD insertion did not show a clinical significance. A lower ease of
PT
Six women asked for additional analgesics in the placebo group versus one in the
AC
LP group (p=0.114). The groups were similar with regard to tenaculum site bleeding.
menstrual pain, and prior perineal laceration requiring suture repair were not
predictors for pain experienced during IUD insertion. Moreover, pain scores were not
9
ACCEPTED MANUSCRIPT
affected by the gynecologist who insert the IUD (p=0.19), prior IUD insertion (p=0.3),
4- Discussion:
P T
Pain during IUD insertion is multifactorial; application of the tenaculum on the
RI
cervical lip can induce severe pain. In addition, insertion of sound and IUD inside the
SC
uterine cavity can add to pain perception [16]. Transmission of Pain from the uterus
occurs through two different visceral pain pathways; Parasympathetic (S2-S4) provides
NU
sensory innervation to the cervix and lower portion of the uterus and sympathetic
MA
(T10-L1) provides sensory innervation to the fundus [17]. In the current RCT, we found
that LP cream applied on the cervix prior to copper T380A IUD insertion significantly
ED
(e.g. gel, injections and spray) and different techniques for administration (intracervical
CE
and paracervical) [8, 18-22]. They have several advantages; however, no studies have
AC
provided strong evidence that various lidocaine formulations provide significant pain
mucous membrane, it is rapidly absorbed within 5-7 minutes compared with 1 hour if
applied to skin [23]. The optimal time for application on the genital mucosa is between
5 and 10 minutes as reported by Van der Burghat et al [24]. In our study, we allowed 7
minutes to elapse between its application and IUD insertion, and based on the results,
this time period was sufficient for the drug to take effect. We found most of the
10
ACCEPTED MANUSCRIPT
applied cream stayed on the cervix at the end of 7 minutes and a cotton swab was
Our results showed significant lower pain scores in all steps of IUD insertion in LP
P T
group as compared with placebo group (p=0.0001). Inserting the IUD tube was the
RI
most painful step and those who received LP had less pain as compared with placebo
SC
group (3[2-3] vs. 6.5[4-8], p=0.0001). In contrast to Tavakolian et al [25], insertion of
the sound was the most painful step in the procedure (5.2±2.3 in the placebo group vs.
NU
3.1±2.5 in LP group, p<0.001). MA
In the current study, the median pain score during IUD insertion was 6.5 (range 4-
8) for women in the placebo group. This is not coincides with the results obtained by
ED
Fouda et al, 2016 that was carried out in Egypt [6]. The baseline characteristics of the
study participants are quite different. In Fouda et al study, the participants were
PT
recruited from Cairo; the capital city of Egypt. In our study, most of women live in rural
CE
areas. The living conditions can affect the way of pain perception for some women.
AC
Safety and efficacy of LP have been revealed consistently in many clinical trials in
office gynecological procedures. Liberty et al., 2007 and Arnau et al., 2014 [13, 26]
proved that LP cream significantly reduces the pain associated with cervical
4.9±2.7, p=0.02 and 1.06 vs. 3.34, p=0.000, respectively). These studies are consistent
with our findings. On the contrary, Arnau et al., 2013 [27] in their study of LP cream
11
ACCEPTED MANUSCRIPT
pain (p=0.07). The small sample size and the non-blinded nature of the study may
LP cream has a high safety profile with rare adverse effects. Reported side effects
P T
include local skin reactions, burning sensation, erythema and pruritis [28]. In our study,
RI
no reported local or systemic side effects in women received LP cream within 24 hours.
SC
This coincides with the study of Liberty et al [13] in which 41 women received LP cream
NU
The strengths of our study include that it was a double blind, randomized, clinical
MA
trial with neither women nor the clinicians being aware of the group assignment. Also,
we included different educational levels of women, as this could affect the perception
ED
Finally, we were able to recruit our calculated sample size for achieving sufficient
PT
The study had its limitations including that the study focused on one type of IUD
AC
as the levonorgestrel IUD is not widely used in Egypt due to its high cost, and
consequently the data are applied only for the copper IUD. A second limitation was the
subjectivity in reporting pain through VAS score, as there are no objective parameters
to evaluate pain. Furthermore, none of the included women were nulliparous as IUD
insertion is not requested by this group in Egypt. Also, adding 7 minutes to the
lengthy procedure with speculum in situ for some women. The participants in this
study did not offer complaints about leaving the speculum in place for 7 additional
12
ACCEPTED MANUSCRIPT
minutes. We used a small plastic speculum in the procedure to avoid any discomfort or
pain induced by the metal one that can affect the pain scores. Also, all participants
viewed the plastic speculum during the pre-insertion counseling. Finally, the possibility
P T
of inter-assessor variability between the four clinicians involved in IUD insertion.
RI
However, the comparable experience in IUD insertion and their equal distribution in
SC
both study groups minimized this risk.
NU
IUD insertion seems to significantly alleviate the induced pain with subsequent easy
MA
insertions. It is easily applied and relatively inexpensive with no side effects. Further
studies are needed to explore its effectiveness in women at high risk for experiencing
ED
severe pain during insertion as nulliparous women or those who only delivered by
elective CS. Moreover, further studies are needed to directly compare its effectiveness
PT
5- Conflict of interest:
AC
None.
13
ACCEPTED MANUSCRIPT
References:
[1] Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness
P T
[2] Buhling KJ, Zite NB, Lotke P, Black K; INTRA Writing Group. Worldwide use of
RI
intrauterine contraception: a review. Contraception. 2014; 89:162-73
SC
[3] Potter J, Rubin SE, Sherman P. Fear of intrauterine contraception among
NU
[4] Hubacher D, Reyes V, Lillo S, Zepeda A, Chen PL, Croxatto H. Pain from copper
MA
intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet
[5] Lopez LM, Bernholc A, Zeng Y, Allen RH, Bartz D, O’Brien PA, et al. Interventions for
pain with intrauterine device insertion. Cochrane Database Syst Rev. 2015;
PT
29;7:CD007373.
CE
[6] Fouda UM, Salah Eldin NM, Elsetohy KA, Tolba HA, Shaban MM, Sobh SM.
AC
Diclofenac plus lidocaine gel for pain relief during intrauterine device insertion. A
[7] Bednarek PH, Micks EA, Edelman AB, Li H, Jensen JT. The effect of nitroprusside on
87:421–5.
[8] Maguire K, Davis A, Rosario Tejeda L, Westhoff C. Intracervical lidocaine gel for
86:214–9.
14
ACCEPTED MANUSCRIPT
[9] Edelman A, Schaefer E, Olson A, Van Houten L, Bedarnek P, Leclair C, et al. Effects of
P T
[10] Zilbert A. Topical anesthesia for minor gynecological procedures: a review. Obstet
RI
Gynecol Surv 2002; 57:171–8.
SC
[11] Friedman PM, Mafong EA, Friedman ES, Geronemus RG. Topical anesthetics
NU
[12] Zullo F, PellicanoM, Stigliano CM, Di Carlo C, Fabrizio A,
MA Nappi C. Topical
prospective, randomized, controlled, double blinded study. Hum Reprod 2007; 22,
CE
1335-9.
AC
EMLA cream on pain of Copper IUD insertion [article in Persian]. Scientific Journal of
114:29-36.
15
ACCEPTED MANUSCRIPT
[16] Scavuzzi A, Souza AS, Costa AA, Amorim MM. Misoprostol prior to inserting an
28:2118-2.
P T
[17] Apte G, Nelson P, Brismée JM, Dedrick G, Justiz R 3rd, Sizer PS Jr. Chronic female
RI
pelvic pain—part 1: clinical pathoanatomy and examination of the pelvic region. Pain
SC
Pract 2012; 12:88-110.
[18] McNicholas CP, Madden T, Zhao Q, Secura G, Allsworth JE, Peipert JF. Cervical
NU
lidocaine for IUD insertional pain: a randomized controlled trial. Am J Obstet Gynecol
MA
2012; 207:384–6.
[19] Allen RH, Raker C, Goyal V. Higher dose cervical 2% lidocaine gel for IUD insertion:
ED
et al. Novel topical formulation of lidocaine provides significant pain relief for
CE
[21] Mody SK, Kiley J, Rademaker A, Gawron L, Stika C, Hammond C. Pain control for
[22] Rapkin RB, Achilles SL, Schwarz EB, Meyn L, Cremer M, Boraas CM, et al. Self-
16
ACCEPTED MANUSCRIPT
for cautery of condyloma acuminata on the vulval mucosa. The effect of timing of
P T
[24] Van der Burght M, Schonemann NK, Laursen JK, Arendt-Nielsen L, Bjerring P.
RI
Duration of analgesia following application of eutectic mixture of local anaesthetics
SC
(EMLA) on genital mucosa. Acta Derm Ven_erelo. 1993; 73:456–8.
NU
prilocaine cream as analgesia for IUD insertion: a prospective, randomized, controlled,
MA
triple blinded study. Glob J Health Sci 2015; 7: 42390.
controlled study. Eur J Obstet Gynecol Reprod Biol 2014; 182: 216–9.
PT
blinded, controlled study. Acta Obstet Gynecol Scand 2013; 92: 978–81.
17
ACCEPTED MANUSCRIPT
Figure captions:
P T
RI
SC
NU
MA
ED
PT
CE
AC
18
ACCEPTED MANUSCRIPT
Table 1: The baseline characteristics of the women according to the medication used prior
to IUD insertion
T
Age (years) 31.1 ± 6.2 31.4 ± 6.7 0.79
P
Residence
RI
Urban 23 (38.3) 27 (45.0) 0.58
SC
Rural 37 (61.7) 33 (55.0)
Education
NU
Some high school 10 (16.7) 13 (21.7)
High school 18 (30.0) 27 (45.0) 0.15
College 20 (33.3) 14 (23.3)
MA
Postgraduate 12 (20.0) 6 (10.0)
ED
19
ACCEPTED MANUSCRIPT
Table 2: The principal outcomes during IUD insertion according to the medication used prior
to the procedure
T
(n=60) (n=60)
P
VAS tenaculum placement 2 [2-3] 4 [3-6] 0.0001
RI
VAS sound insertion 3 [2-3] 6 [5-9] 0.0001
VAS IUD insertion 3 [2-3] 6.5 [4-8] 0.0001
SC
VAS 5 minutes post-insertion 2 [1-2] 3.5 [2-6] 0.0001
Ease of insertion score 2.5 ± 0.98 4.5 ± 1.7 0.001
NU
Need for additional analgesics 1 (1.7) 6 (10.0) 0.11
Tenaculum site bleeding MA 1 (1.7) 2 (3.4) 0.56
Uterine perforation 0 0 ------
Side effects of study medication 0 0 ------
LP; lidocaine-prilocaine, VAS; visual analog scale, IUD; intrauterine device.
ED
All data are presented as n (%), median [inter-quartile range] or mean ± standard deviation
PT
CE
AC
20